BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32374893)

  • 1. The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma.
    Kaufmann C; Kempf W; Mangana J; Cheng P; Emberger M; Lang R; Kaiser AK; Lattmann E; Levesque M; Dummer R; Koelblinger P
    Histopathology; 2020 Sep; 77(3):460-470. PubMed ID: 32374893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.
    Flørenes VA; Faye RS; Maelandsmo GM; Nesland JM; Holm R
    Clin Cancer Res; 2000 Sep; 6(9):3614-20. PubMed ID: 10999753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.
    Gimotty PA; Van Belle P; Elder DE; Murry T; Montone KT; Xu X; Hotz S; Raines S; Ming ME; Wahl P; Guerry D
    J Clin Oncol; 2005 Nov; 23(31):8048-56. PubMed ID: 16258103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCND1 copy number increase and cyclin D1 expression in acral melanoma: a comparative study of fluorescence in situ hybridization and immunohistochemistry in a Chinese cohort.
    Liu J; Yu W; Gao F; Qi S; Du J; Ma X; Zhang Y; Zheng J; Su J
    Diagn Pathol; 2021 Jul; 16(1):60. PubMed ID: 34225728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
    Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
    J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical Expression of Cyclin D1 and Ki-67 in Primary and Metastatic Oral Squamous Cell Carcinoma.
    Nazar M; Naz I; Mahmood MK; Hashmi SN
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):37-41. PubMed ID: 31983161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Peschos D; Goussia A; Mittari E; Charalabopoulos K; Michael M; Salmas M; Vougiouklakis T; Assimakopoulos D; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Jun; 23(2):277-83. PubMed ID: 15354413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions.
    Lebe B; Pabuççuoğlu U; Ozer E
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):160-4. PubMed ID: 17525627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of Ki-67 and cyclin D1 in invasive extramammary Paget's disease.
    Aoyagi S; Akiyama M; Shimizu H
    J Dermatol Sci; 2008 Jun; 50(3):177-84. PubMed ID: 18248961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
    Bachmann IM; Straume O; Akslen LA
    Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
    Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
    Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of telomerase activity and correlation with mitotic and apoptotic indices, Ki-67 and expression of cyclins D1 and A in cutaneous melanoma.
    Miracco C; Pacenti L; Santopietro R; Biagioli M; Fimiani M; Perotti R; Rubegni P; Pirtoli L; Luzi P
    Int J Cancer; 2000 Nov; 88(3):411-6. PubMed ID: 11054670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 immunohistochemical expression and somatic mutations in canine oral melanoma.
    Zamboni C; Brocca G; Ferraresso S; Ferro S; Sammarco A; Dal Corso C; Iussich S; de Andres PJ; Martìnez de Merlo EM; Cavicchioli L; Zappulli V; Castagnaro M
    Vet Comp Oncol; 2020 Jun; 18(2):231-238. PubMed ID: 31503380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease.
    Kneisel L; Strebhardt K; Bernd A; Wolter M; Binder A; Kaufmann R
    J Cutan Pathol; 2002 Jul; 29(6):354-8. PubMed ID: 12135466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence.
    Sawair F; Hassona Y; Irwin C; Stephenson M; Hamilton P; Maxwell P; Gordon D; Leonard A; Napier S
    Asian Pac J Cancer Prev; 2016; 17(3):1243-9. PubMed ID: 27039754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
    de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
    Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible prognostic significance of p53, cyclin D1 and Ki-67 in the second primary malignancy of patients with double primary malignancies.
    Dong M; Wei H; Hou JM; Gao S; Yang DZ; Lin ZH; Jia Y; Ren XP; Gao MH
    Int J Clin Exp Pathol; 2014; 7(7):3975-83. PubMed ID: 25120774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.